141 related articles for article (PubMed ID: 21402620)
1. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis.
Balagula Y; Wu S; Su X; Lacouture ME
Ann Oncol; 2011 Nov; 22(11):2366-2374. PubMed ID: 21402620
[TBL] [Abstract][Full Text] [Related]
2. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
3. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
4. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
5. Acneiform eruption following molecular targeted chemotherapy.
Vaccaro M; Barbuzza O; Pollicino A; Guarneri C
Intern Med J; 2011 Apr; 41(4):361-2. PubMed ID: 21507168
[No Abstract] [Full Text] [Related]
6. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
7. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
11. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
12. [Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Bodet D; Bartralot R; Mollet J; Heras C; García-Patos V
Actas Dermosifiliogr; 2006 Mar; 97(2):148-9. PubMed ID: 16595122
[No Abstract] [Full Text] [Related]
13. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
Minkis K; Garden BC; Wu S; Pulitzer MP; Lacouture ME
J Am Acad Dermatol; 2013 Sep; 69(3):e121-8. PubMed ID: 23357570
[TBL] [Abstract][Full Text] [Related]
14. Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach.
Gobbo M; Ottaviani G; Mustacchi G; Di Lenarda R; Biasotto M
Lasers Med Sci; 2012 Sep; 27(5):1085-90. PubMed ID: 22120470
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.
Schilder RJ; Pathak HB; Lokshin AE; Holloway RW; Alvarez RD; Aghajanian C; Min H; Devarajan K; Ross E; Drescher CW; Godwin AK
Gynecol Oncol; 2009 Apr; 113(1):21-7. PubMed ID: 19162309
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Lin H; Jiang J; Liang X; Zhou X; Huang R
Lung Cancer; 2010 Oct; 70(1):57-62. PubMed ID: 20149474
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
19. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
20. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
